Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

27.41 +0.43 (+1.59%)
Official Closing Price Updated: 7:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,817,857
Open 26.98
Bid (Size) 27.42 (2)
Ask (Size) 27.43 (4)
Prev. Close 26.98
Today's Range 26.95 - 27.46
52wk Range 25.20 - 39.87
Shares Outstanding 5,606,688,356
Dividend Yield 5.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
These two pharma stocks are beloved by income investors. 
Via The Motley Fool

Performance

YTD
-7.80%
-7.80%
1 Month
-3.93%
-3.93%
3 Month
-0.80%
-0.80%
6 Month
-2.66%
-2.66%
1 Year
-30.33%
-30.33%

More News

Read More
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
Via Benzinga
Exposures Product Safety
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
Via Benzinga
Exposures Product Safety
How Is The Market Feeling About Pfizer?
Via Benzinga
Is It Too Late to Buy Pfizer Stock?
Via The Motley Fool
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Via MarketBeat
Exposures COVID-19
Precision Medicine M&A is Transforming the Future of the Biotech Industry
Via AB Newswire
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Via Investor's Business Daily
3 Stocks to Sell as Ozempic Surges in Popularity
Via InvestorPlace
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Via Investor's Business Daily
Exposures Product Safety
What's Going On With Pfizer On Thursday? Pharma Giant's Shares Tick Lower
Via Benzinga
Exposures COVID-19
3 Ultra-High-Yield Dividend Stocks Billionaires Are Sinking Their Teeth Into
Via The Motley Fool
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
From Pfizer Inc.
Via Business Wire
3 Hidden-Gem Value Stocks to Buy and Never Let Go
Via InvestorPlace
7 Recession-Proof Stocks to Buy Now for Peace of Mind
Via InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Via InvestorPlace
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
Via InvestorPlace
Exposures Product Safety
Billionaires Are Buying These 2 Ultra-High-Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.